

CLAIM AMENDMENTS

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

Claims 1-13 (Canceled)

Claim 14 (Currently Amended): A composition for the treatment of asthma, the composition comprising:

montelukast sodium;

an antihistamine selected from the group consisting of cetirizine, and fexofenadine, and combinations thereof; and

a sympathomimetic bronchodilator.

Claim 15 (Original): The composition of claim 14, wherein said sympathomimetic bronchodilator is albuterol.

Claims 16 (Withdrawn): A method for treating asthma comprising the steps of:
preparing a composition comprising:
a first receptor antagonist in the amount of between about 4.0 mg and about 20.0 mg;

a second receptor antagonist in the amount of between about 2.5 mg and about 180.0 mg, said second receptor antagonist being different from said first receptor antagonist;

an adrenergic bronchodilator in the amount of between about 4.0 mg and about 8.0 mg; and

administering said composition to a patient.

Claim 17 (Withdrawn): The method of Claim 16, wherein said first receptor antagonist and said second receptor antagonist are selected from the group consisting of leukotriene receptor antagonists and histamine receptor antagonists.

Claim 18 (Withdrawn): The method of Claim 16, wherein said adrenergic bronchodilator is a beta₂-adrenergic bronchodilator.

Claims 19-22 (Canceled)

Claim 23 (Currently Amended): A composition for the treatment of asthma, the composition comprising:

- (a) a leukotriene receptor antagonist;
- (b) a histamine receptor antagonist selected from the group consisting of cetirizine hydrochloride, and fexofenadine, and combinations thereof; and

(c) an adrenergic bronchodilator.

Claim 24 (Previously Presented): The composition of claim 23, wherein the adrenergic bronchodilator is a beta₂-adrenergic bronchodilator.

Claim 25 (Previously Presented): The composition of claim 23, wherein the histamine receptor antagonist is a histamine receptor H₁-receptor antagonist.

Claim 26 (Canceled)

Claim 27 (Currently Amended): The composition of claim 23, wherein the leukotriene receptor antagonist is selected from the group consisting of:

- (a) montelukast sodium, ~~and~~
- (b) zafirlukast sodium, and combinations thereof.

Claim 28 (Canceled)

Claim 29 (Canceled)

Claim 30 (Withdrawn): The composition of claim 23, wherein

- (a) The histamine receptor antagonist is cetirizine hydrochloride;
- (b) The leukotriene receptor antagonist is montelukast sodium; and

(c) The adrenergic broncodilator is albuterol sulfate.

Claim 31 (Canceled)

Claim 32 (Withdrawn): The composition of claim 23, wherein

- (a) The histamine receptor antagonist is fexofenadine;
- (b) The leukotriene receptor antagonist is montelukast sodium; and
- (c) The adrenergic broncodilator is albuterol sulfate.

Claim 33 (Withdrawn): The composition of claim 23, wherein

- (a) The histamine receptor antagonist is cetirizine hydrochloride;
- (b) The leukotriene receptor antagonist is zafirlukast sodium; and
- (c) The adrenergic broncodilator is albuterol sulfate.

Claim 34 (Withdrawn): The composition of claim 23, wherein

- (a) The histamine receptor antagonist is loratadine;
- (b) The leukotriene receptor antagonist is zafirlukast sodium; and
- (c) The adrenergic broncodilator is albuterol sulfate.

Claim 35 (Withdrawn): The composition of claim 23, wherein

- (a) The histamine receptor antagonist is fexofenadine;
- (b) The leukotriene receptor antagonist is zafirlukast sodium; and

(c) The adrenergic broncodilator is albuterol sulfate.

Claim 36 (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 23.

Claim 37 (Withdrawn): The method of claim 36, wherein the amount of the histamine receptor antagonist in the composition is between about 2.5 mg and about 180 mg.

Claim 38 (Withdrawn): The method of claim 36, wherein the amount of the leukotriene receptor antagonist in the composition is between about 4 mg and about 20 mg.

Claim 39 (Withdrawn): The method of claim 36, wherein the amount of the adrenergic broncodilator in the composition is between about 4 mg and about 8 mg.

Claim 40 (Withdrawn): The method of claim 36, wherein the amount of the adrenergic broncodilator in the composition is about 2 mg.

Claim 41 (Withdrawn): The method of claim 36, wherein the amount of the adrenergic broncodilator in the composition is about 0.1mg/kg of the patient's body weight.

Claim 42 (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 29.

Claim 43 (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 30.

Claim 44 (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 31.

Claim 45 (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 32.

Claim 46 (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 33.

Claim 47 (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 34.

Claim 48 (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 35.